argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
26 aug 2016 - 07:00
Statutaire naam
argenx SE
Titel
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
Bericht
• Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
• Phase 2 study in first auto-immune indication planned to start by year-end
• Cash position strengthened by $40M upfront payment from AbbVie and €30M private placement
Management to host conference call today at 3 pm CET / 9 am EDT
26 August 2016
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its second quarter business update and half year financial results for 2016, in accordance with IFRS as adopted by the European Union.
Datum laatste update: 21 december 2025